Switching from Dupilumab to Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of Efficacy After Treatment With Dupilumab in JADE DARE

Authors

Claire Clibborn (ORCID: https://orcid.org/0000-0002-2586-891X)
Jonathan I. Silverberg (ORCID: https://orcid.org/0000-0003-3686-7805)
Eric L. Simpson (ORCID: https://orcid.org/0000-0003-0853-0252)
Andrew Pink (ORCID: https://orcid.org/0000-0001-5151-5539)
Erman Güler (ORCID: https://orcid.org/0009-0006-1240-5269)
Pinaki Biswas (ORCID: https://orcid.org/0009-0009-3494-4142)
Stephan Weidinger (ORCID: https://orcid.org/0000-0003-3944-252X)
Gary Chan (ORCID: https://orcid.org/0000-0002-1338-132X)

Institutions

Oregon Health & Science University (US)
Pfizer (United States) (US)
King's College London (GB)
Pfizer (United Kingdom) (GB)
George Washington University (US)
Guy's and St Thomas' NHS Foundation Trust (GB)
University Hospital Schleswig-Holstein (DE)
University of Lübeck (DE)

Publication Details

Journal: Dermatology and Therapy
Published: 2025-02-01
DOI: https://doi.org/10.1007/s13555-024-01320-y
Citations: 7
Primary Topic: Dermatology and Skin Diseases
Type: article
Field-Weighted Citation Impact: 14.03

Funders

Pfizer

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Switching from Dupilumab to Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of Efficacy After Treatment With Dupilumab in JADE DARE

Claire Clibborn, Jonathan I. Silverberg, Eric L. Simpson, Andrew Pink et al.

Feb 1, 2025

7 citations

Dermatology and Therapy

Dermatology and Skin Diseases

14.03

article

Switching from Dupilumab to Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of Efficacy After Treatment With Dupilumab in JADE DARE

Claire Clibborn, Jonathan I. Silverberg, Eric L. Simpson, Andrew Pink, Erman Güler, Pinaki Biswas, Stephan Weidinger, Gary Chan

February 1, 2025article en

7 citations

Abstract

No abstract available for this paper.

Dermatology and TherapyVol. 15(2)

Oregon Health & Science University (US), Pfizer (United States) (US), King's College London (GB), Pfizer (United Kingdom) (GB), George Washington University (US), Guy's and St Thomas' NHS Foundation Trust (GB), University Hospital Schleswig-Holstein (DE), University of Lübeck (DE)

Pfizer

Openalex Percentile: Top 1%

Dermatology and Skin Diseases

14.03

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Switching from Dupilumab to Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of Efficacy After Treatment With Dupilumab in JADE DARE — Claire Clibborn, Jonathan I. Silverberg, et al. · Dermatology and Therapy (2025) | TGRS Research Map | TGRS